{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:16:14Z","timestamp":1790252174601,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LTAUSA18083"],"award-info":[{"award-number":["LTAUSA18083"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GACR 19\u201301417S"],"award-info":[{"award-number":["GACR 19\u201301417S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV 17\u201328980A"],"award-info":[{"award-number":["AZV 17\u201328980A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.actbio.2020.11.014","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T21:51:43Z","timestamp":1605045103000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-2016","authenticated-orcid":false,"given":"Robert","family":"Pola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pokorn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Vo\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u0161ka","family":"B\u00f6hmov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pechar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-6000","authenticated-orcid":false,"given":"Jana","family":"Karolov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-1391","authenticated-orcid":false,"given":"Jan","family":"Pankr\u00e1c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"\u0160efc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7141-8074","authenticated-orcid":false,"given":"Karel","family":"Helman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-6073","authenticated-orcid":false,"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2020.11.014_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","author":"Vose","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184417","article-title":"Advances in molecular biology and targeted therapy of mantle cell lymphoma","author":"Klener","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2020.11.014_bib0003","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2020.11.014_bib0004","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2020.11.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2483","article-title":"Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma","author":"Klener","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","author":"Visco","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2020.11.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","author":"Lefr\u00e8re","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2020.11.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","author":"Merli","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31361","article-title":"Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma","author":"Romaguera","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.actbio.2020.11.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","author":"Ellison","year":"1968","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2020.11.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1983.1.11.689","article-title":"High-dose cytosine arabinoside in non-Hodgkin's lymphoma","author":"Kantarjian","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/BF00194527","article-title":"Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside","author":"Capizzi","year":"1996","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.actbio.2020.11.014_bib0015","doi-asserted-by":"crossref","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.actbio.2020.11.014_bib0016","article-title":"Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine","author":"Capizzi","year":"1991","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1983.1.12.763","article-title":"Alteration of the pharmacokinetics of high-dose Ara-C by its metabolite, high Ara-U in patients with acute leukemia","author":"Capizzi","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","author":"Tran","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.actbio.2020.11.014_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2020.11.014_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.actbio.2020.11.014_bib0021","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","article-title":"Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis","volume":"17","author":"Glantz","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0022","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2020.11.014_bib0023","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2020.11.014_bib0024","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.biomac.8b01616","article-title":"Polymer cancerostatics targeted by recombinant antibody fragments to GD2-positive tumor cells","volume":"20","author":"Pola","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2020.11.014_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2018.09.018","article-title":"Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging","volume":"289","author":"Etrych","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2020.11.014_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/molecules201119664","article-title":"Anti-lymphoma efficacy comparison of anti-CD20 monoclonal antibody-targeted and non-targeted star-shaped polymer-prodrug conjugates","author":"Lidick\u00fd","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.actbio.2020.11.014_bib0027","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1021\/acs.molpharmaceut.5b00531","article-title":"A novel platinum-maurocalcine conjugate induces apoptosis of human glioblastoma cells by acting through the ROS-ERK\/AKT-p53 pathway","volume":"12","author":"Aroui","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2020.11.014_bib0028","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2012.06.029","article-title":"HPMA copolymer-doxorubicin conjugates: the effects of molecular weight and architecture on biodistribution and in vivo activity","volume":"164","author":"Etrych","year":"2012","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2020.11.014_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2013.11.011","article-title":"Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl) methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage","volume":"174","author":"Nakamura","year":"2014","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2020.11.014_bib0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.33549\/physiolres.933424","article-title":"The pH-Dependent and Enzymatic Release of Cytarabine From Hydrophilic Polymer Conjugates","volume":"65","author":"Pola","year":"2016","journal-title":"Physiol. Res."},{"key":"10.1016\/j.actbio.2020.11.014_bib0031","article-title":"Acid-triggered release of native gemcitabine conjugated in polyketal nanoparticles for enhanced anticancer therapy","author":"Zhong","year":"2020","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2020.11.014_bib0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00141-8","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation","volume":"64","author":"Ulbrich","year":"2000","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2020.11.014_bib0033","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.reactfunctpolym.2006.05.002","article-title":"Synthesis and properties of new N-(2-hydroxypropyl)-methacrylamide copolymers containing thiazolidine-2-thione reactive groups","volume":"66","author":"\u0160ubr","year":"2006","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.actbio.2020.11.014_bib0034","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/macp.1997.021980408","article-title":"Biodegradable drug carriers based on poly(ethylene glycol) block copolymers","volume":"198","author":"Pechar","year":"1997","journal-title":"Macromol. Chem. Phys."},{"key":"10.1016\/j.actbio.2020.11.014_bib0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/labinvest.2014.61","article-title":"Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research","volume":"94","author":"Klanova","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.actbio.2020.11.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2020.11.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-159","article-title":"Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents","author":"Klanova","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2020.11.014_bib0038","doi-asserted-by":"crossref","first-page":"10906","DOI":"10.1039\/C7NR03306K","article-title":"A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging","volume":"9","author":"Koziolova","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2020.11.014_bib0039","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2020.11.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1039\/C7NR09355A","article-title":"Interaction of spin-labeled HPMA-based nanoparticles with human blood plasma proteins-the introduction of protein-corona-free polymer nanomedicine","author":"Klepac","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2020.11.014_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-015-0379-4","article-title":"HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases","author":"Dozono","year":"2016","journal-title":"Target. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0042","doi-asserted-by":"crossref","DOI":"10.4149\/neo_2016_515","article-title":"Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model","author":"Klanova","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.actbio.2020.11.014_bib0043","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2013.825906","article-title":"High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial","author":"Laurell","year":"2014","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.actbio.2020.11.014_bib0044","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2020.11.014_bib0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2020.11.014_bib0046","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2020.11.014_bib0047","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120306577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120306577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:31:55Z","timestamp":1761672715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706120306577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["S1742706120306577"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2020.11.014","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2020.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}